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Patient medication educationAbstract Background: The purpose of this national survey is to evaluate hospital pharmacy prac-
tice in the Riyadh region of Saudi Arabia. The results of the survey pertaining to the monitoring
and patient education of the medication use process were presented.
Methods: We have invited pharmacy directors from all 48 hospitals in the Riyadh region to par-
ticipate in a modiﬁed-American Society of Health-System Pharmacists (ASHP) survey question-
naire. The survey was conducted using similar methods to those of the ASHP surveys.
Results: The response rate was 60.4% (29/48). Most hospitals (23, 79%) had pharmacists regu-
larly monitor medication therapy for patients. Of these hospitals, 61% had pharmacists monitoring
medication therapy daily for less than 26% of patients, 17%monitored 26–50% of patients and 22%
monitored more than half of patients daily. In 41% of hospitals, pharmacists routinely monitored
serum medication concentrations or their surrogate markers; 27% gave pharmacists the authority
to order initial serum medication concentrations, and 40% allowed pharmacists to adjust dosages.
Pharmacists routinely documented their medication therapy monitoring activities in 52% of hospi-
tals. Overall, 74% of hospitals had an adverse drug event (ADE) reporting system, 59% had a mul-
tidisciplinary committee responsible for reviewing ADEs, and 63% had a medication safety
362 M.S. Alsultan et al.committee. Complete electronic medical record (EMR) systems were available in 15% of hospitals
and 81% had a partial EMR system. The primary responsibility for performing patient medication
education lays with nursing (37%), pharmacy (37%), or was a shared responsibility (26%). In 44%
of hospitals, pharmacists provided medication education to half or more inpatients and in a third of
hospitals, pharmacists gave medication education to 26% or more of patients at discharge.
Conclusion: Hospital pharmacists in the Riyadh region are actively engaged in monitoring med-
ication therapy and providing patient medication education, although there is considerable oppor-
tunity for further involvement.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The role of the hospital pharmacist is to ensure the safe, effec-
tive, and economic use of medicines. This can be accomplished
through various measures including monitoring drug therapy
and educating patients on their medication use. Studies have
shown that the participation of pharmacists in drug therapy
management facilitates patient adherence to therapy, improves
outcomes of drug therapy and increases the cost-effectiveness
of treatment (Borenstein et al., 2003; Bozovich et al., 2000;
Yanchick, 2000). Providing patient education and counseling
improves patient compliance, therapeutic outcomes and qual-
ity of life as well as increasing their understanding about med-
ication and lifestyle modiﬁcations in chronic illness (Malathy
et al., 2011; Mehos et al., 2000; Padiyara et al., 2011).
In Saudi Arabia, published studies assessing hospital phar-
macy practice are very limited. Hence, in 2010, we designed a
project in collaboration with the King Saud University College
of Pharmacy, the Saudi Pharmaceutical Society (SPS) and the
AmericanSociety ofHealth-SystemPharmacists (ASHP) to sur-
vey the current state of hospital pharmacy practice in the coun-
try. We used a modiﬁed survey based on the published ASHP
survey, which focuses on assessing the role of pharmacists in
managing and improving themedication-use system. The survey
has been conducted in hospitals of the Riyadh region and is or-
ganized according to the six steps in the medication-use system:
prescribing, transcribing, dispensing, administration, monitor-
ing, and patient education. The results for the ﬁrst four steps
have already been published (Alsultan et al., 2012; European
Association of Hospital Pharmacists, 2005).
The third part in the series focuses on the monitoring and pa-
tient education steps of the medication use process in hospitals of
the Riyadh region. To the best of our knowledge, this is the ﬁrst
attempt to assess the role of hospital pharmacists in patient mon-
itoring and education. In assessing the role of pharmacists in pa-
tient monitoring and education, the present study seeks to
describe and characterize the trends in pharmacist’s monitoring
of medication therapy, and describe the monitoring activities of
pharmacists. This study also describes the methods used to mon-
itor adverse drug events (ADEs), characterizes internal and exter-
nal ADE reporting, and identiﬁes patient education and
counseling activities. In addition, this studydescribes theworking
hours of pharmacy operation, staff training, and the readiness of
pharmacy graduates for practice in a hospital pharmacy setting.
Findings from this survey will provide an overview of the
current practices in drug monitoring and patient education,
and should act as a benchmark at local and national levels.
The results will also help to track progress over time and will
help to identify opportunities for strategic initiatives and poli-
cies at a national level to improve practice.2. Methods
2.1. Survey
A survey questionnaire as pertinent to hospital pharmacy in
Saudi Arabia was prepared by modiﬁcation, addition and sub-
traction from ASHP survey questions in consultation with
ASHP survey members. The survey details were also discussed
with some of the hospital pharmacy directors in Riyadh prior
to ﬁnalizing the survey. For this report, the major domains of
the medication use process studied were monitoring and pa-
tient education. The survey was conducted using methods sim-
ilar to those of the ASHP surveys (Pedersen et al., 2008, 2009,
2010, 2011). Some questions were constructed to allow multi-
ple options to be given as responses.
The pharmacy directors of 48 hospitals in the Riyadh re-
gion according to Ministry of Health (MOH) records (Saudi
Ministry of Health Portal, 2011) were contacted to participate
in the survey. The survey questionnaires were collected upon
completion. To increase the response rate, three attempted fol-
low-ups were made within three months and respondents were
offered a complimentary copy of the 2010 Saudi National For-
mulary (SNF) to encourage their participation. Any hospital
pharmacy that did not respond during the study period was
considered a non-responder. Each booklet of the survey ques-
tionnaire was assigned a serial number.
2.2. Statistics
Data were entered into Predictive Analytics Software (PASW)
Advanced Statistics version 18 (formerly called SPSS Advance
Statistics, SPSS Inc., Chicago, Illinois) licensed for King Saud
University. The data are summarized using descriptive statis-
tics, categorized by hospital size as small (less than 100 beds),
medium (100–299 beds) or large (300 or more beds).
3. Results
Twenty-nine of the 48 hospital pharmacies in the Riyadh region
responded to the survey giving a response rate of 60.4%. The
characteristics of respondent hospitals are shown in Table 1.
3.1. Medication therapy monitoring
For the purposes of this survey, medication therapy monitor-
ing occurs after a patient has received a medication. Medica-
tion therapy monitoring activities include monitoring
therapeutic drug levels, monitoring patient outcomes, monitor-
ing patient laboratory results, adverse drug event monitoring,
adjustments in medication regimens, etc.
Table 1 Size, ownership and accreditation of respondent’s
hospital.
Characteristics Hospitals (n= 29)
N (%)
Hospital size (Number of staﬀed beds)
Small
<50 2 (6.9)
50–99 4 (13.8)
Total 6 (20.7)
Medium
100–199 7 (24.1)
200–299 3 (10.3)
Total 10 (34.4)
Large
300–399 3 (10.3)
400–599 4 (13.8)
P600 4 (13.8)
Total 11 (37.9)
Missing-No Response 2 (6.9)
Occupied beds
<50 4 (13.8)
50–99 4 (13.8)
100–199 6 (20.7)
200–299 3 (10.3)
300–399 1 (3.4)
400–599 3 (10.3)
P600 3 (10.3)
Missing-No Response 5 (17.3)
Ownership
Government hospital 14 (48.3)
Private hospital 15 (51.7)
Accreditation
Accredited 16 (55.1)
Table 2 Number (%) of hospitals with groups who regularly perf
monitored by pharmacists.
Characteristics Hospitals
Small <1
Patients monitored by pharmacists each day (n = 23)*
<26% 2 (8.7)
26 to 50% 0 (0.0)
51 to 75% 2 (8.7)
75% 1 (4.3)
Groups regularly perform medication therapy monitoring (n = 25)a
Distributive pharmacists 3 (12.0)
Clinical pharmacists 1 (4.0)
Integrated distributive/clinical pharmacists 0 (0.0)
Pharmacy residents 1 (4.0)
Pharmacy students 0 (0.0)
No pharmacists regularly perform patient monitoring services 1 (4.0)
Percentages based on number of hospital respondents
a Multiple options could be selected.
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that pharmacists regularly monitored medication therapy for
patients. The survey asked respondents to report the percent-
age of patients monitored by pharmacists in their hospital on
a daily basis. About 61% of respondents indicated that phar-
macists monitored 625% of all patients each day. An addi-
tional 17.4% indicated that pharmacists monitored 26–50%
of patients each day (Table 2).
In those hospitals where monitoring regularly occurred, the
service was performed by clinical pharmacists 36% of the time,
distributive pharmacists 24%, pharmacy residents in 16% and
integrated distributive-clinical pharmacists in 12% (Table 2).
3.1.1. Methods to identify patients in need of monitoring
There are various ways to identify which patients are most
likely to beneﬁt from the medication therapy-monitoring activ-
ities of a pharmacist.
This survey showed that 39% of hospitals identiﬁed pa-
tients for monitoring by using one or more of the following
methods: a formalized list of speciﬁc medications, speciﬁc med-
ical or surgical services, disease state, and abnormal laboratory
values that prompt dosage adjustments (Table 3). Further-
more, 22% of hospitals identiﬁed patients for monitoring by
high cost medications and 17% used other methods.
3.1.2. Activities implemented to improve monitoring
Several of our surveyed hospitals had implemented a variety of
activities within the past three years to promote medication
therapy monitoring by pharmacists. The commonly reported
activities were implementation of clinical pharmacy services
(40%), computerized prescriber order entry (28%), increased
hiring of clinical pharmacy staff (28%), increased access to pa-
tient-speciﬁc data to pharmacists (28%), implemented satellite
pharmacies (24%), expanded pharmacy technician responsibil-
ities (20%), and implemented automated dispensing systems
(16%). Activities implemented less frequently included re-de-
ployed pharmacists to patient care units and decentralized
pharmacist order entries (Table 3).orm medication therapy monitoring and percentage of patients
engaged in activity
00 n (%) Medium (100–299) n (%) LargeP 300 n (%) Total n (%)
6 (26.1) 6 (26.1) 14 (60.9)
2 (8.7) 2 (8.7) 4 (17.4)
0 (0.0) 1 (4.3) 3 (13.0)
1 (4.3) 0 (0.0) 2 (8.6)
1 (4.0) 2 (8.0) 6 (24.0)
1 (4.0) 7 (28.0) 9 (36.0)
2 (8.0) 1 (4.0) 3 (12.0)
1 (4.0) 2 (8.0) 4 (16.0)
0 (0.0) 0 (0.0) 0 (0.0)
7 (28.0) 2 (8.0) 10 (40.0)
Table 3 Number (%) of hospitals using methods to identify patients in need of monitoring and activities implemented to promote
medication therapy monitoring by pharmacists.
Characteristics Hospitals engaged in activity
Small <100 n (%) Medium (100–299) n (%) LargeP 300 n (%) Total n (%)
Methods to identify patients in need of monitoring (n = 23)a
Formalized list of medications (e.g., high-risk medication) 3 (13.0) 3 (13.0) 3 (13.0) 9 (39.1)
Speciﬁc medical or surgical services 2 (8.7) 2 (8.7) 5 (21.7) 9 (39.1)
Disease state 2 (8.7) 4 (17.4) 3 (13.0) 9 (39.1)
Abnormal lab value changes requiring dosage adjustment 1 (4.3) 2 (8.7) 6 (26.1) 9 (39.1)
High cost medications (e.g., IVIG, Factor VII) 1 (4.3) 1 (4.3) 3 (13.0) 5 (21.6)
Informal process (e.g., individual pharmacist selection) 2 (8.7) 2 (8.7) 5 (21.7) 9 (39.1)
Other 1(4.3) 1(4.3) 2 (8.7) 4 (17.4)
Activities Implemented to Promote Medication Therapy Monitoring(n = 25)a
Increased hiring of clinical pharmacy staﬀ 0 2 (8.0) 5 (20.0) 7 (28.0)
Implemented satellite pharmacies 1 (4.0) 1 (4.0) 4 (16.0) 6 (24.0)
Implemented computerized prescriber order entry 3 (12.0) 1(4.0) 3 (12.0) 7 (28.0)
Implemented an automated dispensing system 1 (4.0) 1 (4.0) 2 (8.0) 4 (16.0)
Re-deployed pharmacists to patient care units 0 (0.0) 0 (0.0) 2 (8.0) 2 (8.0)
Decentralized pharmacist order entry 0 (0.0) 1 (4.0) 1 (4.0) 2 (8.0)
Expanded pharmacy technician responsibilities 1 (4.0) 3 (12.0) 1 (4.0) 5 (20.0)
Increased access to patient-speciﬁc data 1 (4.0) 3 (12.0) 3 (12.0) 7 (28.0)
Promoted value of clinical pharmacy services 1 (4.0) 1 (4.0) 8 (32.0) 10 (40.0)
Other 0 (0.0) 0 (0.0) 1(4.0) 1 (4.0)
Percentages based on number of hospital respondents
a Multiple options could be selected.
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In 41% of all surveyed hospitals, pharmacists routinely moni-
tored serum medication concentrations or their surrogate
markers such as vancomycin, aminoglycoside levels, interna-
tional normalization ratio (INR) etc. (Table 4). In 27% of hos-
pitals, pharmacists had the authority, by protocol, to order an
initial measurement of serum medication concentrations, and
40% allowed pharmacists to adjust a dosage for a monitored
medication. Additionally, 46% of hospitals ensured that phar-
macists accurately recorded and evaluated allergies prior to
administration of medication.
3.1.4. Documentation and location of medication therapy
monitoring activities
For the purposes of this survey, routine patient–proﬁle moni-
toring is deﬁned as the review of patient proﬁles (e.g., medica-
tion administration records, medical record, and pharmacy
medication proﬁle) after the medication order has been pro-
cessed and the treatment initiated. This deﬁnition does not in-
clude the monitoring that occurs upon initial processing of the
medication order.
The survey showed that pharmacists routinely documented
their medication therapy monitoring activities in 52% of
hospitals.
Allowing for multiple locations of documentation, pharma-
cists most frequently documented these activities in patient
medical records (36%), pharmacy patient proﬁles (32%), and
medication administration records (27%) (Table 4).
3.1.5. Access to electronic information
Computer access to laboratory data was readily available to
pharmacists to monitor medication therapy in 56% of hospi-
tals (Table 4).3.1.6. Medical record system and organizational program
Only 15% of hospitals, classiﬁed as large hospitals, had a com-
plete electronic medical record (EMR) system with no paper
records whereas 81% of hospitals had a partial EMR with
some components still using paper charts (Table 4).
An organizational program with appropriate pharmacy
involvement in order to achieve signiﬁcant annual documented
improvement in the safety of all steps in medication use was
present in 44% of hospitals.
3.2. Adverse drug events (ADEs) monitoring and reporting
Since operational deﬁnitions of ADEs vary, hospital pharmacy
directors were provided with the following deﬁnition of ADEs:
‘‘An adverse drug event is an injury resulting from the use of,
or not using, a needed medication. For the purpose of this sur-
vey, consider both adverse drug reactions and medication er-
rors that result in adverse clinical outcomes together as
adverse drug events.’’
3.2.1. Review of ADEs
Overall, 74% of hospitals had an ADE reporting system and
59% had a multidisciplinary committee (including physicians,
pharmacists, and nurses) that was responsible for the review,
analysis, education, policy formation and corrective action re-
lated to adverse drug events. In addition, 63% of hospitals had
a medication safety committee (Table 5).
3.2.2. Methods to identify ADEs
Recipients of the survey were asked to identify which methods
pharmacists use to routinely monitor patients for ADEs
(Table 5). The most commonly used methods were an ADE
Table 4 Number (%) of hospitals with pharmacists involved in therapeutic drug monitoring, documenting their monitoring, location
of documentation and having electronic access to patient information.
Characteristics Hospitals engaged in activity
Small <100
n (%)
Medium
(100–299) n (%)
LargeP 300
n (%)
Total
n (%)
Therapeutic drug monitoring
Monitor medication levels (n= 27) 2 (7.4) 4 (14.8) 5 (18.5) 11 (40.7)
Authorized to order serum medication level measurement (n= 26) 1 (3.8) 2 (7.7) 4 (15.4) 7 (26.9)
Authorized to dosage adjustment for a routinely monitored medication (n= 25) 2 (8.0) 3 (12.0) 5 (20.0) 10 (40.0)
Allergies are accurately recorded and evaluated prior to
medicine administration (n= 26)
2 (7.7) 4 (15.4) 6 (23.1) 12 (46.2)
Medication therapy monitoring documentation (n = 27)
Documentation of monitoring activities 3 (11.1) 4 (14.8) 7 (25.9) 14 (51.9)
Locations of Medication Therapy Monitoring Documentation (n = 22)a
Patient medical record 3 (13.6) 0 (0.0) 5 (22.7) 8 (36.4)
Medication administration record 1 (4.5) 4 (18.2) 1 (4.5) 6 (27.3)
Pharmacy patient proﬁle 1(4.5) 2 (9.1) 4 (18.2) 7 (31.8)
Other 0 (0.0) 2 (9.1) 1(4.5) 3 (13.6)
Electronic access to laboratory data (n = 27)
Electronic access to laboratory data to pharmacists 2 (7.4) 5 (18.5) 8 (29.6) 15 (55.6)
Medical record system (n = 26)
Entire electronic medical record system 0 (0.0) 0 (0.0) 4 (15.4) 4 (15.4)
Some components are electronic 6 (23.1) 9 (34.6) 6 (23.1) 21 (80.8)
Not applicable 0 (0.0) 1(3.8) 0 (0.0) 1 (3.8)
Percentages based on number of hospital respondents
a Multiple options could be selected.
Table 5 Number (%) of hospitals using an ADE reporting system.
Characteristics Hospitals engaged in activity
Small <100
n (%)
Medium
(100–299) n (%)
LargeP 300
n (%)
Total
n (%)
ADE reporting system and committees (27)
ADE reporting system 3 (11.1) 7 (25.9) 10 (37.1) 20 (74.1)
Medication safety committee 3 (11.1) 8 (29.7) 6 (22.2) 17 (63.0)
Multidisciplinary committee 1 (3.7) 7 (25.9) 8 (29.7) 16 (59.3)
Methods routinely use to identify ADEs (27)a
Routine review of lab values 2 (7.4) 2 (7.4) 3 (11.1) 7 (25.9)
Therapeutic drug monitoring 3 (11.1) 2 (7.4) 4 (14.8) 9 (33.3)
Pharmacists round with physicians 1 (3.7) 2 (7.4) 5 (18.5) 8 (29.6)
Pharmacists round independent of physicians 0 1 (3.7) 5 (18.5) 6 (22.2)
Adverse drug events hotline 1 (3.7) 0 1 (3.7) 2 (7.4)
Notiﬁcation from nursing 1 (3.7) 5 (18.5) 6 (22.2) 12 (44.4)
Through patient counseling/interaction 1 (3.7) 2 (7.4) 4 (14.8) 7 (25.9)
ADE incident reporting system 1 (3.7) 6 (22.2) 7 (25.9) 14 (51.8)
None of the above methods used 2 (7.4) 2 (7.4) 0 4 (14.8)
ADE Reporting practice (n = 26)a
Report regularly to the medication safety committee and P&T committee 3 (11.5) 6 (23.1) 8 (30.8) 17 (65.4)
Externally to FDA or the international agency 0 1 (3.8) 0 1 (3.8)
Saudi Food and Drug Authority (SFDA) 3 (11.5) 4 (15.4) 7 (26.9) 14 (53.8)
Ministry of Health (MOH) 4 (15.4) 4 (15.4) 3 (11.5) 11 (42.3)
Manufacturers of pharmaceutical products 3 (11.5) 2 (7.7) 3 (11.5) 8 (30.7)
Other 1 (3.8) 0 0 1 (3.8)
Percentages based on number of hospital respondents
a Multiple options could be selected.
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(44%), therapeutic drug monitoring (33%), pharmacists round
with physicians to assess ADEs (30%), routine review of lab val-ues (26%), and through patient counseling/interaction (26%).
Less frequently used methods included pharmacists round inde-
pendent of physicians (22%), and having an ADE hotline (7%).
Table 6 Number (%) of hospitals performing patient medication education and counseling and the method used to select patient for
counseling.
Characteristics Hospitals engaged in activity
Small <100
n (%)
Medium (100–299)
n (%)
LargeP 300
n (%)
Total
n (%)
Primary responsibility for medication education and counseling (n = 27)
Patient education by nursing 7 (25.9) 2 (7.4) 1 (3.7) 10 (37.0)
Patient education by pharmacy 0 6 (22.2) 4 (14.8) 10 (37.0)
Patient education by nursing and pharmacy 0 2 (7.4) 3 (11.1) 5 (18.5)
None/Other 0 0 2 (7.4) 2 (7.4)
Method to select patient for counseling (n = 23)a
All patients are counseled 0 1 (4.3) 3 (13.1) 4 (17.4)
Patients discharged on more medications 3 (13.1) 1 (4.3) 4 (17.4) 8 (34.8)
Patients discharged on highly complex or high-risk medication regimens 3 (13.1) 3 (13.1) 5 (21.7) 11 (47.9)
Upon patient request 1 (4.3) 2 (8.7) 1 (4.3) 4 (17.4)
Upon physician order 0 1 (4.3) 4 (17.4) 5 (21.7)
Upon nurse request 0 1 (4.3) 1 (4.3) 2 (8.7)
History of noncompliance 0 0 0 0
Disease-based focus 0 0 1 (4.3) 1 (4.3)
Drug–drug interactions 0 0 2 (8.7) 2 (8.7)
Newly prescribed medications 1 (4.3) 2 (8.7) 1 (4.3) 4 (17.4)
Percentages based on number of hospital respondents
a Multiple options could be selected.
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ADEs were reported internally to the medication safety com-
mittee, and pharmacy and therapeutics (P & T) committee in
65% of hospitals (Table 5).3.2.4. External ADE reporting
Of those hospitals that reported ADEs externally, the Saudi
Food and Drug Authority (54%), Ministry of Health (42%),
and the manufacturer of pharmaceutical products (31%) were
the main recipients. Only one hospital (4%) reported serious
ADEs externally to the US-FDA or another international
agency (Table 5).3.3. Patient medication education and counseling
For the purposes of this survey, patient education and counsel-
ing are deﬁned as a combination of teaching activities that fo-
cus on keeping patients informed about their health condition,
treatment plans, medication therapy, and self-care manage-
ment to facilitate changes in behavior for improvement and
maintenance of health. Patient education and counseling
may also include incidental, informal, or spontaneous ex-
changes of information that may be initiated by a speciﬁc need,
concern, or situation at a given time.3.3.1. Department responsible for medication education and
counseling
The nursing department and the pharmacy department each
had equal opportunities to perform patient medication educa-
tion and counseling (37% each). However, 26% of hospitals
reported this task as a shared responsibility between pharmacy
and nursing or another department. (Table 6).3.3.2. Proportion of patients receiving medication education and
counseling
Overall, 44% of hospitals reported that at least half of all pa-
tients received medication education from a pharmacist during
their inpatient hospital stay and a third of hospitals provided
patient medication education to 26% or more of patients at
discharge.
3.3.3. Method to select patient for medication education and
counseling
Less than half of the hospitals (46%) used some method to se-
lect patients for medication education and counseling by phar-
macists. Of those that used a method to select patients, the
identiﬁcation of patients discharged on highly complex or
high-risk medication regimens (48%), patients discharged on
more medications (35%) and upon physician order (22%) were
the most commonly used (Table 6). Less commonly used meth-
ods to select patients included newly prescribed medications,
upon nurse or patient request, or medications with potential
drug–drug interactions.
3.3.4. Follow-up after discharge
Overall, 21% of hospitals had pharmacists follow up high-risk
patients about their medications after they were discharged
from the hospital.
3.3.5. Required documentation
Twenty-four percent of the pharmacy directors reported that
their pharmacists were required to document inpatient medica-
tion counseling in the patient’s medical record.
3.4. Hours of pharmacy operation
Most hospitals (79%) reported that they provided 24-h phar-
macy services.
Table 7 Readiness of pharmacy graduates to practice independently in hospitals.
Characteristics New pharmacy graduate
(non-residency) n= 25 n (%)
New pharmacy practice
resident (n= 25) n (%)
Well prepared, minimal orientation and training required 4 (16.0) 7 (28.0)
Prepared, reasonable orientation and training required 9 (36.0) 13 (52.0)
Unprepared, extensive training and remediation required 6 (24.0) 9 (36.0)
Not applicable 6 (24.0) 17 (68.0)
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Over half of the hospitals (56%) reported having an executive
level pharmacy position that met the job proﬁle of the chief
pharmacy ofﬁcer, regardless of the actual job title.
3.6. Full time equivalent (FTE) positions
Data on FTE positions were not analyzed due to variable re-
sponses. The data indicated that pharmacy directors had some
difﬁculty in calculating FTE positions, possibly due to misun-
derstanding the deﬁnition.
3.7. Staff training
To train newly hired pharmacy technicians, 81.5% of hospitals
used on the job training with observation, 18.5% used in-
house self-study of books or videos, and 7.4% used in-house
didactic training (lecture component with written exam).
Pharmacy directors acknowledged their contribution to the
introductory or advanced pharmacy practice experience
(IPPE/APPE) for pharmacy students in their pharmacy
departments. More than 62% of pharmacy directors believed
that pharmacy student training contributes to patient care.
3.8. Readiness of pharmacy graduates
The readiness of new pharmacy graduates to practice indepen-
dently is shown in Table 7.
4. Discussion
Our study is the ﬁrst to provide descriptive data on the status
of pharmacy practice pertaining to monitoring and patient
education in hospitals in the Riyadh region of Saudi Arabia.
We consider our survey response rate of 60.4% as good.
Although, the survey sample size is relatively small we believe
that it gives a fair representation of hospital pharmacies in the
Kingdom of Saudi Arabia as the survey was conducted in the
Riyadh region of Saudi Arabia with a population of 6.2 mil-
lion and where about 40% of the major hospitals in Saudi Ara-
bia are situated (Saudi Ministry of Health Portal, 2011).
Despite the fact that the majority of the surveyed hospitals
(79.3%) reported that pharmacists regularly monitored medi-
cation therapy for patients, about 60% of hospitals provide
monitoring on a daily basis to less than 26% of patients. This
indicates that there is a signiﬁcantly lower level of daily drug
monitoring in Saudi Arabia compared with the United States
of America (US) as the ASHP survey conducted in 2009
showed only 20% of hospitals providing a drug monitoringservice on a daily basis to less than 26% of patients (Pedersen
et al., 2010). In addition, although the percentage of clinical
pharmacists providing the monitoring service in our hospitals
is comparable to the US (36% vs. 44%), we have fewer inte-
grated distributive-clinical pharmacists performing the same
task here than in US hospitals (12% vs. 65%).
The lack of skilled clinical pharmacists is likely to be the
main reason for the lower level of monitoring service provided
by our surveyed hospitals compared to the US. Currently,
most employed hospital pharmacists hold a bachelor degree
in pharmaceutical science with minimal clinical skills learned
during ﬁve years of education. However, in 2001, King Abdu-
laziz University Jeddah, Saudi Arabia, introduced the ﬁrst
doctor of pharmacy (Pharm. D) program. The purpose of
the program is to train pharmacists to assume greater respon-
sibility in providing pharmaceutical care service and to pro-
mote the role of a pharmacist as a direct patient care
provider in various clinical setting. Currently, 15 colleges of
pharmacy offer the Pharm. D curriculum across the Kingdom
and 4,500 clinical pharmacists (based on the assumption that
30 graduates/college/year) are expected to graduate by 2020.
In contrast, in the US, a doctor of pharmacy program has been
available since the 1960s, currently all accredited schools and
colleges of pharmacy in the US offer the Pharm. D degree as
a mandatory entry level for pharmacists. We believe that the
introduction of the Pharm. D program will gradually expand
pharmaceutical care services in Saudi Arabia. In addition,
expansion in postgraduate residency training programs e.g.
PGY-1 and PGY-2 will further enhance the quality of pharma-
ceutical care. In Saudi Arabia, there is an ongoing national res-
idency program and this is considered equivalent to a PGY-1,
that only graduates general clinical pharmacists without a fo-
cus on a speciﬁc specialty (Al-Haidari and Al-Jazairi, 2010;
Al-Qadheeb et al., 2012).
Studies have shown that pharmacist interventions can max-
imize therapeutic efﬁcacy while minimizing AEs and improv-
ing patient outcomes (Chumney and Robinson, 2006; Kaboli
et al., 2006). Monitoring high-risk medications and abnormal
laboratory value changes that require dosage adjustment can
reduce ADEs and improve clinical outcome among hospital-
ized patients (Szekendi et al., 2006). The present study has
shown that only 39% of our hospitals use abnormal labora-
tory values and high risk patient-speciﬁc medical information
to identify which patients require daily monitoring compared
with 75% of surveyed hospitals in the ASHP surveys (Pedersen
et al., 2010). Due to lack of well-trained clinical pharmacists in
many of the surveyed hospitals, we suggest that pharmacy
directors should consider increasing their use of abnormal lab-
oratory values and high-risk patient-speciﬁc medical informa-
tion by pharmacists to maximize therapeutic drug monitoring
outcome.
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pitals here in promoting therapy monitoring compared to hos-
pitals in the US. This was especially evident in areas such as
promoting the value of clinical pharmacy services (40% vs.
56%), increasing access to patient-speciﬁc data (28% vs.
44%), implementing an automated dispensing system (16%
vs. 30%), and deploying of pharmacists to patient care units
(8% vs. 23.5%) (Pedersen et al., 2010).
The beneﬁts of measuring plasma or whole blood medica-
tions concentration or biochemical markers to achieve opti-
mized dosage regimens are well-established (Touw et al.,
2007). Our survey ﬁndings indicated that only 41% of hospi-
tals had pharmacists routinely monitor serum medication con-
centrations or their surrogate markers to evaluate drug
therapy outcome and toxicity. This is considerably lower than
the rate reported in the ASHP survey where more than 92% of
hospitals engaged in this activity (Pedersen et al., 2010). Our
survey also highlights that clinical pharmacists have a less pro-
nounced role regarding initial ordering of drugs level and
adjusting the medication dosage that has been monitored than
their US counterparts. In US hospitals, 80% of clinical phar-
macists were authorized, by protocol, to order an initial drug
level compared to only 27% in our surveyed-hospitals and
79% of US hospitals allowed their clinical pharmacists to ad-
just the dosage of a medication compared to 40% in the King-
dom (Pedersen et al., 2010).
While pharmacists understand the importance of docu-
menting relevant issues pertaining to medication management
in medical records, they do not always achieve their goal here.
As per Saudi Ministry of Health, all clinical interventions
involving changes of patient orders shall be appropriately doc-
umented on the patient’s medical record using clinical pharma-
cist intervention form in such a manner to allow others to
easily understand and re-trace activities or actions (Saudi Min-
istry of Health., 2010). We found that pharmacists routinely
documented their medication therapy monitoring activities in
only 52% of hospitals here compared to 85% in the US
(Pedersen et al., 2010). On the other hand, about 63% of hos-
pitals in Ireland and Spain kept a written report on pharmacist
intervention for inpatients in the pharmacy (European Associ-
ation of Hospital Pharmacists, 2005). This indicates that there
is the potential for a signiﬁcant improvement in this domain.
The primary method to improve the efﬁciency of monitor-
ing is to make laboratory data readily accessible to pharma-
cists. The new Joint Commission on Accreditation of
Healthcare Organizations (JCAHO) Medication Management
and Use Standard MM.1.10 (Rich, 2004) requires that ‘‘Pa-
tient-speciﬁc information is readily accessible to those involved
in the medication management system.’’ The present study has
shown that only 56% of the surveyed hospitals provide phar-
macists computer access to laboratory information. This is an
unexpectedly low compared with the US where most pharma-
cists (93%) have access to laboratory data using electronic sys-
tems (Pedersen et al., 2010). In a Canadian survey, 43% of
respondents reported that their laboratory system is interfaced
with the medication order entry system and 54% of respon-
dents reported that they accessed laboratory data through
view-only terminals (Hospital Pharmacy in Canada Editorial
Board, 2011). Hence, this is another area with considerable
opportunity for improvement here.
The broad adoption of EMR systems have shown to reduce
medical errors, improve health, and major health care savings(Hillestad et al., 2005). Over 75% of physicians at a teaching
hospital in Saudi Arabia have indicated that the use of EMR
systems has a positive impact on work and quality of care
(Nour El Din, 2007). Our ﬁndings indicated that 15% of hos-
pitals had a complete EMR system with no paper records. This
compares favorably with the US, as the ASHP survey found
that only 8.8% of US hospitals had a complete EMR system
with no paper records (Pedersen et al., 2010). This ﬁgure seems
over-inﬂated, as respondents of this survey might have consid-
ered the presence of CPOE as a complete EMR. A relatively
older study in the US (Jha et al., 2009) reported that only
1.5% of US hospitals have a comprehensive EMR system
(i.e., present in all clinical units), and an additional 7.6% have
a basic system (i.e., present in at least one clinical unit).
Adverse drug reaction reporting systems can help minimize
harm from medicines at local, regional, national, and interna-
tional level (Reza and Emmerton, 2005). Our ﬁndings show
that more than half of the pharmacists are using an ADE inci-
dent/ occurrence reporting system to routinely monitor pa-
tients for ADEs. Pharmacists in the US are using similar
methods but with a higher frequency (Pedersen et al., 2010).
Moreover, adverse drug reactions are monitored by pharma-
cists in 82% of Italian hospitals and in more than 70% of Irish,
Spanish and Dutch hospitals (European Association of Hospi-
tal Pharmacists, 2005).
The primary purpose of reporting is to document variances,
examine system errors and learn from experience. When an ad-
verse event occurs in a hospital, it is reported to multidisciplin-
ary committees, an investigation is carried out to uncover the
causes, and changes are made to prevent a recurrence (Vincent
et al., 2000; Vincent et al., 1998). Our result shows that signif-
icantly lesser (59%) hospitals had a multidisciplinary commit-
tee(s), which was/were responsible for the review, analysis,
education, policy formation and corrective action related to
ADEs compared to most hospitals (89%) in the US (Pedersen
et al., 2010).
A good internal reporting system ensures that all responsi-
ble parties (healthcare providers and patients) are aware of
major hazards including ADEs (Lucian, 2002). The analysis
of the reports will highlight the causes and assist in determin-
ing the incidence of ADRs. The current results indicate that in
only two thirds of hospitals (65%) ADEs were reported inter-
nally to the medication safety committee and/or Pharmacy and
therapeutics (P & T) committee. Ideally, internal reporting of
ADEs in any hospital should be near 100%. The level of
reporting of ADEs found in this survey is suboptimal and in
need of signiﬁcant improvement.
Data suggest that counseling patients in general reduces
medication discrepancies, errors, and improves adherence
(Al-Rashed et al., 2002; Lipton and Bird, 1994; Smith et al.,
1997). Our result indicates that the primary departments
responsible for patient medication education and counseling
were pharmacy and nursing departments (37%) each. The re-
sults suggest that pharmacy departments here have a more
dominant role in education and counseling patients than in
US hospitals. For instance, the most recent ASHP survey re-
ported that the vast majority of hospitals (89.0%) assigned pri-
mary responsibility for performing patient medication
education and counseling to nurses while pharmacists were
responsible for performing these tasks in only 5.9% of institu-
tions (Pedersen et al., 2010). Our ﬁndings may provide a
benchmark for the proportion of patients receiving medication
Monitoring and patient education practice in Saudi Arabia 369education during their inpatient hospital stay and at discharge
in Saudi Arabia and it will allow tracking progress over time.
Unfortunately, the ASHP survey conducted in 2009 reported
that the proportion of patients receiving patient education by
pharmacists either during their hospital stay or when they
are discharged has not signiﬁcantly changed over the past nine
years (Pedersen et al., 2010).
Comprehensive counseling for every patient is not always
feasible and only 17% of the hospitals in this survey counseled
all patients. Therefore, focusing interventions for speciﬁc pa-
tients is often necessary and it may be appropriate to arrange
specialized counseling for patients who are prescribed high-
risk medications or medications that require special adminis-
tration skills (Forster et al., 2003; Gandhi et al., 2003). As
expected, our results showed that the two groups of patients
most commonly selected for medication education and coun-
seling by pharmacists were patients discharged on highly com-
plex or high-risk medication regimens (48%) and those
discharged on greater number of medications (35%). Counsel-
ing patients taking several medications at a time is particularly
important, as studies have reported that patients prescribed
more than ﬁve medications may not only experience added dif-
ﬁculty, but they are also at greater risk of ADEs (Gandhi et al.,
2003; Kripalani et al., 2008).
One ﬁfth of hospitals had pharmacists follow up high-risk
patients about their medications after their discharge from
hospital in our survey. The post discharge medication review
and telephone follow-up by a pharmacist reduce the hospital-
ization rate, total health care costs, and a lower rate of pre-
ventable ADEs 30 days after discharge (Jack et al., 2009;
Schnipper et al., 2006). Studies have also shown that better
documentation of a patient’s medications reduces ADEs dur-
ing and after hospitalization (Kaboli et al., 2006; Schnipper
et al., 2006). Only a quarter of our survey respondents reported
that pharmacists were required to document inpatient medica-
tion counseling in the patient’s medical record. Hence, further
improvements are needed in both the documentation and the
post discharge follow - up.
5. Conclusion
Hospital pharmacists in the Riyadh region are actively en-
gaged in monitoring medication therapy and providing patient
medication education, although there is considerable opportu-
nity for further improvement.
Conﬂicts of interest and source of funding
The authors declare no conﬂicts of interest.Acknowledgements
The authors would like to thank the Saudi Pharmaceutical
Society (SPS) and the American Society of Health-System
Pharmacists (ASHP) for their support. They also would like
to thank the pharmacy directors who participated in the survey
and Ted Morton Pharm D., BCPS (AQ-ID), Associate Profes-
sor of Clinical Pharmacy, King Saud University College of
Pharmacy, Riyadh, Saudi Arabia for his review of survey ques-
tionnaire as pertinent to Saudi Arabia.References
Al-Haidari, K.M., Al-Jazairi, A.S., 2010. Establishment of a national
pharmacy practice residency program in Saudi Arabia. Am. J.
Health-Syst. Pharm. 67, 1467–1470.
Al-Qadheeb, N.S., Alissa, D.A., Al-Jedai, A., Ajlan, A., Al-Jazairi,
A.S., 2012. The ﬁrst international residency program accredited by
the American society of health-system pharmacists. Am. J. Pharm.
Educ. 76, 1–4.
Al-Rashed, S.A., Wright, D.J., Roebuck, N., Sunter, W., Chrystyn, H.,
2002. The value of inpatient pharmaceutical counselling to elderly
patients prior to discharge. Br. J. Clin. Pharmacol 54, 657–664.
Alsultan, M.S., Khurshid, F., Mayet, A.Y., Al-jedai, A.H., 2012.
Hospital pharmacy practice in Saudi Arabia: dispensing and
administration in the Riyadh region. Saudi Pharm. J. 20, 307–315.
Borenstein, J.E., Graber, G., Saltiel, E., Wallace, J., Ryu, S., Archi, J.,
Deutsch, S., Weingarten, S.R., 2003. Physician-pharmacist coman-
agement of hypertension: a randomized, comparative trial. Phar-
macotherapy 23, 209–216.
Bozovich, M., Rubino, C.M., Edmunds, J., 2000. Effect of a clinical
pharmacist-managed lipid clinic on achieving national cholesterol
education program low-density lipoprotein goals. Pharmacother-
apy 20, 1375–1383.
Chumney, E.C., Robinson, L.C., 2006. The effects of pharmacist
interventions on patients with polypharmacy. Pharm. Pract. 4, 103–
109.
European Association of Hospital Pharmacists, E.A.H.P., 2005.
EAHP survey 2005. Available at http://www.eahp.eu/sites/
default/ﬁles/ﬁles/EAHP%202005%20Sur-
vey%20V07b09TMG%20A4.pdf (site visited 20121218).
Forster, A.J., Murff, H.J., Peterson, J.F., Gandhi, T.K., Bates, D.W.,
2003. The incidence and severity of adverse events affecting patients
after discharge from the hospital. Ann. Intern. Med. 138, 161–167.
Gandhi, T.K., Weingart, S.N., Borus, J., Seger, A.C., Peterson, J.,
Burdick, E., Seger, D.L., Shu, K., Federico, F., Leape, L.L., Bates,
D.W., 2003. Adverse drug events in ambulatory care. N. Engl. J.
Med. 348, 1556–1564.
Hillestad, R., Bigelow, J., Bower, A., Girosi, F., Meili, R., Scoville, R.,
Taylor, R., 2005. Can electronic medical record systems transform
health care? Potential health beneﬁts, savings, and costs. Health
Aff. (Millwood) 24, 1103–1117.
Hospital Pharmacy in Canada Editorial Board, 2011. Hospital
pharmacy in Canada report 2009/2010. Available from http://
www.lillyhospitalsurvey.ca/hpc2/content/2010_report/
2009_2010_full_e.pdf (site visited 20120116).
Jack, B.W., Chetty, V.K., Anthony, D., Greenwald, J.L., Sanchez,
G.M., Johnson, A.E., Forsythe, S.R., O’Donnell, J.K., Paasche-
Orlow, M.K., Manasseh, C., Martin, S., Culpepper, L., 2009. A
reengineered hospital discharge program to decrease rehospitaliza-
tion: a randomized trial. Ann. Intern. Med. 150, 178–187.
Jha, A.K., DesRoches, C.M., Campbell, E.G., Donelan, K., Rao,
S.R., Ferris, T.G., Shields, A., Rosenbaum, S., Blumenthal, D.,
2009. Use of electronic health records in US hospitals. N. Engl. J.
Med. 360, 1628–1638.
Kaboli, P.J., Hoth, A.B., McClimon, B.J., Schnipper, J.L., 2006.
Clinical pharmacists and inpatient medical care: a systematic
review. Arch. Intern. Med. 166, 955–964.
Kripalani, S., Price, M., Vigil, V., Epstein, K.R., 2008. Frequency and
predictors of prescription-related issues after hospital discharge. J.
Hosp. Med. 3, 12–19.
Lipton, H.L., Bird, J.A., 1994. The impact of clinical pharmacists’
consultations on geriatric patients’ compliance and medical care
use: a randomized controlled trial. Gerontologist 34, 307–315.
Lucian, L.L., 2002. Reporting of adverse events. N. Engl. J. Med. 347,
1633–1638.
Malathy, R., Narmadha, M., Ramesh, S., Alvin, J.M., Dinesh, B.N.,
2011. Effect of a diabetes counseling programme on knowledge,
370 M.S. Alsultan et al.attitude and practice among diabetic patients in Erode district of
South India. J. Young Pharm. 3, 65–72.
Mehos, B.M., Saseen, J.J., MacLaughlin, E.J., 2000. Effect of
pharmacist intervention and initiation of home blood pressure
monitoring in patients with uncontrolled hypertension. Pharmaco-
therapy 20, 1384–1389.
Nour El Din, M.M., 2007. Physicians’ use of and attitudes toward
electronic medical record system implemented at a teaching
hospital in saudi arabia. J. Egypt Public Health Assoc. 82, 347–364.
Padiyara, R.S., D’Souza, J.J., Rihani, R.S., 2011. Clinical pharmacist
intervention and the proportion of diabetes patients attaining
prevention objectives in a multispecialty medical group. J. Manag.
Care Pharm. 17, 456–462.
Pedersen, C.A., Schneider, P.J., Scheckelhoff, D.J., 2008. ASHP
national survey of pharmacy practice in hospital settings: prescrib-
ing and transcribing–2007. Am. J. Health-Syst. Pharm. 65, 827–
843.
Pedersen, C.A., Schneider, P.J., Scheckelhoff, D.J., 2009. ASHP
national survey of pharmacy practice in hospital settings: dispens-
ing and administration–2008. Am. J. Health-Syst. Pharm. 66, 926–
946.
Pedersen, C.A., Schneider, P.J., Scheckelhoff, D.J., 2010. ASHP
national survey of pharmacy practice in hospital settings: moni-
toring and patient education–2009. Am. J. Health-Syst. Pharm. 67,
542–558.
Pedersen, C.A., Schneider, P.J., Scheckelhoff, D.J., 2011. ASHP
national survey of pharmacy practice in hospital settings: prescrib-
ing and transcribing–2010. Am. J. Health-Syst. Pharm. 68, 669–
688.
Reza, S.M.R., Emmerton, L.M., 2005. An introduction to adverse
drug reaction reporting systems in different countries. IJPP 13, 91–
100.
Rich, D.S., 2004. New JCAHO medication management standards for
2004. Am. J. Health-Syst. Pharm. 61, 1349–1358.Saudi Ministry of Health Portal, M.O.H., 2011. Available from http://
www.moh.gov.sa/eServices/Directory/Pages/HospitalsService.aspx.
Saudi Ministry of Health., 2010. Institutional Policy and Procedure.
Clinical Pharmacist Intervention Documentation. Available at
http://www.sccs-sa.org/download/policy-procedures/new/Pol-
icy%20&%20Procedures/Pharmacy%20Policies/
Clinical%20Pharmacist%20intervention%20documentation.pdf.
Schnipper, J.L., Kirwin, J.L., Cotugno, M.C., Wahlstrom, S.A.,
Brown, B.A., Tarvin, E., Kachalia, A., Horng, M., Roy, C.L.,
McKean, S.C., Bates, D.W., 2006. Role of pharmacist counseling
in preventing adverse drug events after hospitalization. Arch.
Intern. Med. 166, 565–571.
Smith, L., McGowan, L., Moss-Barclay, C., Wheater, J., Knass, D.,
Chrystyn, H., 1997. An investigation of hospital generated phar-
maceutical care when patients are discharged home from hospital.
Br. J. Clin. Pharmacol. 44, 163–165.
Szekendi, M.K., Sullivan, C., Bobb, A., Feinglass, J., Rooney, D.,
Barnard, C., Noskin, G.A., 2006. Active surveillance using
electronic triggers to detect adverse events in hospitalized patients.
Qual. Saf. Health Care 15, 184–190.
Touw, D.J., Neef, C., Thomson, A.H., Vinks, A.A., 2007. Cost-
effectiveness of therapeutic drug monitoring: an update. EJHP Sci.
13, 83–91.
Vincent, C., Taylor-Adams, S., Chapman, E.J., Hewett, D., Prior, S.,
Strange, P., Tizzard, A., 2000. How to investigate and analyse
clinical incidents: clinical risk unit and association of litigation and
risk management protocol. BMJ 320, 777–781.
Vincent, C., Taylor-Adams, S., Stanhope, N., 1998. Framework for
analysing risk and safety in clinical medicine. BMJ 316, 1154–1157.
Yanchick, J.K., 2000. Implementation of a drug therapy monitoring
clinic in a primary-care setting. Am. J. Health-Syst. Pharm. 57
(Suppl 4), S30–34.
